Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience-Reference-Cited by-同舟云学术

Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience

Published:2013-12-19 Issue:26 Volume:122 Page:4279-4286
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Peffault de Latour Régis¹,Porcher Raphael²,Dalle Jean-Hugues³,Aljurf Mahmoud⁴,Korthof Elisabeth T.⁵,Svahn Johanna⁶,Willemze Roelof⁷,Barrenetxea Cristina⁸,Mialou Valerie⁹,Soulier Jean¹⁰,Ayas Mouhab⁴,Oneto Rosi¹¹,Bacigalupo Andrea¹¹,Marsh Judith C. W.¹²,Peters Christina¹³,Socie Gerard¹¹⁴,Dufour Carlo¹⁵

Affiliation:

1. Service d’Hématologie Greffe and

2. Department de Biostatistique Médicale, Assistance Publique des Hôpitaux de Paris–Hôpital Saint Louis, Paris, France;

3. Service d’Hématologie Pédiatrique, AP-HP-Hôpital Robert Debré Paris, France;

4. Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia;

5. Pediatric Stem Cell Transplantation, Leiden University Medical Center, Leiden, The Netherlands;

6. Pediatric Hematology, Ospedale Gaslini, Genova, Italy;

7. Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands;

8. Hospital Vall d’Hebron, Barcelona, Spain;

9. Institut d’Hematologie et d' Oncologie Pediatrique, Lyon, France;

10. Institut National pour la Santé et la Recherche Médicale Unité 944 and Hematology Laboratory, Saint-Louis Hospital and University Paris-Diderot, Paris, France;

11. Department of Hematology, Ospedale San Martino, Genova, Italy;

12. Haematological Medicine, King's College Hospital/King's College London, London, United Kingdom;

13. Stem Cell Transplantation Unit, St. Anna Children's Hospital and European Group for Blood and Marrow Transplantation-Pediatric Diseases Working Party, Vienna, Austria;

14. Université Paris-Diderot, Paris, France U728, Paris; and

15. Pediatric Hematology, G. Gaslini Institute, Genova, Italy

Abstract

Key Points The best survival benefit of HSCT is observed in patients with FA who are transplanted before 10 years with bone marrow after a fludarabine-based regimen. Long-term outcome of patients with FA after transplantation is mainly affected by secondary malignancies and chronic graft-versus-host disease.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/26/4279/1372812/4279.pdf

Reference50 articles.

1. Alter BP.,2003

2. Association of complementation group and mutation type with clinical outcome in fanconi anemia.;Faivre;Blood,2000

3. Cancer incidence in persons with Fanconi anemia.;Rosenberg;Blood,2003

4. A 20-year perspective on the International Fanconi Anemia Registry (IFAR).;Kutler;Blood,2003

5. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.;Quentin;Blood,2011

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral cancer and oral potentially malignant disorders in patients with Fanconi anemia – A systematic review;Oral Oncology;2024-03

2. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT;The Lancet Haematology;2023-12

3. Outcome of allogeneic stem cell transplant for Fanconi anemia in India;Pediatric Hematology and Oncology;2023-11-27

4. Pediatric Bone Marrow Failure: A Broad Landscape in Need of Personalized Management;Journal of Clinical Medicine;2023-11-20

5. Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia;Bone Marrow Transplantation;2023-10-17